John Snow Labs Launches FDA-Ready Patient Journey Platform for Real-World Evidence
Event summary
- John Snow Labs introduced the Patient Journey Intelligence (PJI) platform, the first secondary-use data platform designed to meet the FDA's finalized guidance on real-world evidence (RWE) for medical devices, announced on January 21, 2026.
- The platform integrates multimodal data, including structured EHR fields, clinician notes, pathology and imaging reports, labs, imaging, and claims data, to create longitudinal patient journeys.
- PJI embeds governance directly into its core architecture, ensuring end-to-end data lineage, full model and transformation lineage, and human-in-the-loop validation workflows.
- The platform is deployed entirely within an organization’s own infrastructure, ensuring sensitive clinical data never leaves the organization’s security perimeter.
The big picture
The launch of John Snow Labs' PJI platform comes as the FDA's December 2025 guidance shifts the focus of real-world evidence to include unstructured clinical narratives and longitudinal patient experiences. This move underscores the growing importance of data provenance, quality, and reliability in regulatory decision-making. The platform's emphasis on governance and transparency positions it as a key player in the evolving landscape of healthcare AI and regulatory compliance.
What we're watching
- Regulatory Adoption
- How quickly healthcare organizations will adopt the PJI platform to meet FDA's new RWE requirements.
- Data Integration
- Whether the platform's ability to integrate multimodal data will set a new standard for RWE.
- Competitive Response
- The pace at which competitors will develop similar FDA-ready RWE platforms.
Related topics